TY - JOUR
T1 - Epigenetics in NAFLD/NASH
T2 - Targets and therapy
AU - Sodum, Nalini
AU - Kumar, Gautam
AU - Bojja, Sree Lalitha
AU - Kumar, Nitesh
AU - Rao, C. Mallikarjuna
N1 - Funding Information:
The authors are thankful to Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal for the constant support. The authors are also grateful to the All India Council for Technical Education (AICTE), Government of India, New Delhi for providing National Doctoral Fellowship to Mr. Gautam Kumar [Grant Number: AICTE/NDF/53120 (Ap. No.)].
Funding Information:
The authors are thankful to Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal for the constant support. The authors are also grateful to the All India Council for Technical Education ( AICTE ), Government of India, New Delhi for providing National Doctoral Fellowship to Mr. Gautam Kumar [Grant Number: AICTE/NDF/53120 (Ap. No.)].
Publisher Copyright:
© 2021 Elsevier Ltd
PY - 2021/5
Y1 - 2021/5
N2 - Recently non-alcoholic fatty liver disease (NAFLD) has grabbed considerable scientific attention, owing to its rapid increase in prevalence worldwide and growing burden on end-stage liver diseases. Metabolic syndrome including obesity, diabetes, and hypertension poses a grave risk to NAFLD etiology and progression. With no drugs available, the mainstay of NAFLD management remains lifestyle changes with exercise and dietary modifications. Nonselective drugs such as metformin, thiazolidinediones (TZDs), ursodeoxycholic acid (UDCA), silymarin, etc., are also being used to target the interrelated pathways for treating NAFLD. Considering the enormous disease burden and the unmet need for drugs, fresh insights into pathogenesis and drug discovery are required. The emergence of the field of epigenetics offers a convincing explanation for the basis of lifestyle, environmental, and other risk factors to influence NAFLD pathogenesis. Therefore, understanding these epigenetic modifications to target the primary cause of the disease might prove a rational strategy to prevent the disease and develop novel therapeutic interventions. Apart from describing the role of epigenetics in the pathogenesis of NAFLD as in other reviews, this review additionally provides an elaborate discussion on exploiting the high plasticity of epigenetic modifications in response to environmental cues, for developing novel therapeutics for NAFLD. Besides, this extensive review provides evidence for epigenetic mechanisms utilized by several potential drugs for NAFLD.
AB - Recently non-alcoholic fatty liver disease (NAFLD) has grabbed considerable scientific attention, owing to its rapid increase in prevalence worldwide and growing burden on end-stage liver diseases. Metabolic syndrome including obesity, diabetes, and hypertension poses a grave risk to NAFLD etiology and progression. With no drugs available, the mainstay of NAFLD management remains lifestyle changes with exercise and dietary modifications. Nonselective drugs such as metformin, thiazolidinediones (TZDs), ursodeoxycholic acid (UDCA), silymarin, etc., are also being used to target the interrelated pathways for treating NAFLD. Considering the enormous disease burden and the unmet need for drugs, fresh insights into pathogenesis and drug discovery are required. The emergence of the field of epigenetics offers a convincing explanation for the basis of lifestyle, environmental, and other risk factors to influence NAFLD pathogenesis. Therefore, understanding these epigenetic modifications to target the primary cause of the disease might prove a rational strategy to prevent the disease and develop novel therapeutic interventions. Apart from describing the role of epigenetics in the pathogenesis of NAFLD as in other reviews, this review additionally provides an elaborate discussion on exploiting the high plasticity of epigenetic modifications in response to environmental cues, for developing novel therapeutics for NAFLD. Besides, this extensive review provides evidence for epigenetic mechanisms utilized by several potential drugs for NAFLD.
UR - http://www.scopus.com/inward/record.url?scp=85103677036&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103677036&partnerID=8YFLogxK
U2 - 10.1016/j.phrs.2021.105484
DO - 10.1016/j.phrs.2021.105484
M3 - Review article
C2 - 33771699
AN - SCOPUS:85103677036
SN - 1043-6618
VL - 167
JO - Pharmacological Research
JF - Pharmacological Research
M1 - 105484
ER -
